Patrick Lamy Sells 2,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 2,000 shares of Akero Therapeutics stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $54.14, for a total value of $108,280.00. Following the sale, the vice president now directly owns 32,573 shares in the company, valued at approximately $1,763,502.22. The trade was a 5.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Patrick Lamy also recently made the following trade(s):

• On Tuesday, June 10th, Patrick Lamy sold 919 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $49,626.00.
• On Monday, June 2nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.31, for a total value of $201,240.00.
• On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.00, for a total value of $200,000.00.
• On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $42.49, for a total transaction of $339,920.00.

Akero Therapeutics Price Performance

NASDAQ:AKRO traded down $0.49 during mid-day trading on Friday, reaching $54.42. 253,464 shares of the stock were exchanged, compared to its average volume of 1,010,656. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average price of $45.51 and a 200 day moving average price of $40.94. Akero Therapeutics, Inc. has a 1-year low of $21.02 and a 1-year high of $58.40. The firm has a market capitalization of $4.34 billion, a PE ratio of -27.96 and a beta of -0.16.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of ($1.01) by $1.91. Research analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AKRO. Voya Investment Management LLC boosted its stake in shares of Akero Therapeutics by 302.9% during the 1st quarter. Voya Investment Management LLC now owns 82,471 shares of the company's stock worth $3,338,000 after acquiring an additional 62,000 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Akero Therapeutics by 4.7% in the 1st quarter. Rhumbline Advisers now owns 110,687 shares of the company's stock valued at $4,481,000 after purchasing an additional 5,001 shares during the period. Strs Ohio acquired a new stake in Akero Therapeutics during the 1st quarter worth about $510,000. Intech Investment Management LLC lifted its stake in Akero Therapeutics by 54.4% during the first quarter. Intech Investment Management LLC now owns 58,522 shares of the company's stock valued at $2,369,000 after buying an additional 20,620 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Akero Therapeutics by 53.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,909 shares of the company's stock valued at $4,449,000 after buying an additional 38,458 shares in the last quarter.

Analysts Set New Price Targets

AKRO has been the subject of several recent research reports. HC Wainwright upped their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup dropped their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Bank of America upped their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday, May 27th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.